Rezolute, Inc. logo

Rezolute, Inc.

NASDAQ:RZLT

Overview | Financials
Company Name Rezolute, Inc.
Symbol RZLT
Currency USD
Price 4.9
Market Cap 283,921,190
Dividend Yield 0%
52-week-range 0.9 - 6.186
Industry Biotechnology
Sector Healthcare
CEO Mr. Nevan Charles Elam J.D.
Website https://www.rezolutebio.com

An error occurred while fetching data.

About Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic

Related Stocks

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

11.23 USD

Selecta Biosciences, Inc. logo

Selecta Biosciences, Inc.

SELB

0.881 USD

FONAR Corporation logo

FONAR Corporation

FONR

15.14 USD

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

CTMX

1.03 USD

Achilles Therapeutics plc logo

Achilles Therapeutics plc

ACHL

1.14 USD

Financials

Numbers are in millions USD

Numbers are in millions USD